Wockhardt Limited

rs,

forward-looking statement in this presentation, whether as a result of changes in underlying factors, new information, future events or otherwise. The information in this document have been collected w

INR 3,373

globe 2 R&D centers one each in India, UK 6 Investor Conference | 04 June 2026 Key Financials INR 3,373 Cr. FY26 Income INR 630 Cr. FY26 EBITDA INR 238 Cr. FY26 PBT 51% Y-o-Y EBITDA growth1 0.10 Net

INR 630

h in India, UK 6 Investor Conference | 04 June 2026 Key Financials INR 3,373 Cr. FY26 Income INR 630 Cr. FY26 EBITDA INR 238 Cr. FY26 PBT 51% Y-o-Y EBITDA growth1 0.10 Net Debt : Equity ratio2 INR

INR 238

tor Conference | 04 June 2026 Key Financials INR 3,373 Cr. FY26 Income INR 630 Cr. FY26 EBITDA INR 238 Cr. FY26 PBT 51% Y-o-Y EBITDA growth1 0.10 Net Debt : Equity ratio2 INR 662 Cr. Cash & Cash Equiv

51%

ne 2026 Key Financials INR 3,373 Cr. FY26 Income INR 630 Cr. FY26 EBITDA INR 238 Cr. FY26 PBT 51% Y-o-Y EBITDA growth1 0.10 Net Debt : Equity ratio2 INR 662 Cr. Cash & Cash Equivalents3 FY26 vs

INR 662

630 Cr. FY26 EBITDA INR 238 Cr. FY26 PBT 51% Y-o-Y EBITDA growth1 0.10 Net Debt : Equity ratio2 INR 662 Cr. Cash & Cash Equivalents3 FY26 vs FY25 1. 2. As on 31st March 2026, excluding promoter debt 3.

23%

2026 7 Investor Conference | 04 June 2026 P e r f o r m a n c e 0 1 Specialty Business growth 23% Contribution to revenues of novel antibiotics & biosimilars Emrok delivered strong growth of ~50%

50%

23% Contribution to revenues of novel antibiotics & biosimilars Emrok delivered strong growth of ~50%; Market leading anti-MRSA brand 27% Biotech business growth Production scale-up: 2x for Human In

27%

l antibiotics & biosimilars Emrok delivered strong growth of ~50%; Market leading anti-MRSA brand 27% Biotech business growth Production scale-up: 2x for Human Insulin & 1.5x for Glargine 8 Invest

2x

growth of ~50%; Market leading anti-MRSA brand 27% Biotech business growth Production scale-up: 2x for Human Insulin & 1.5x for Glargine 8 Investor Conference | 04 June 2026 P e r f o r m a n c

1.5x

leading anti-MRSA brand 27% Biotech business growth Production scale-up: 2x for Human Insulin & 1.5x for Glargine 8 Investor Conference | 04 June 2026 P e r f o r m a n c e 0 2 Regional Business

13%

Investor Conference | 04 June 2026 P e r f o r m a n c e 0 2 Regional Business contribution UK +13% YoY growth Specialty Injectables 39% 28% Emerging Markets +35% YoY growth Strategic business pa

Public Market

1

Market potential

1

Public Market

Health economics & cost effectiveness Patient Access Program PUBLIC · Access for Public Payors including States Sources: Wockhardt India commercial assessment; ICMR AMR data 2024; NPPA formulary guidelines; Ayushman Bharat PMJAY inclusion criteria 31 Investor Conference | 04 June 2026 E M D i s e a s e L a n d s c a p e Carbapenem Resistance Burden in Emerging Markets ~ 1.5 Mn+ CR cases in EM markets · High unmet need for managing CR organism infections ~1.5Mn+ Estimated CR cases per year across EM’s • Resistance is rising rapidly across EM markets — outpacing treatment options • Multiple resistance mechanisms make infections Hard- to-Treat or Difficult-to-Treat ~10% to 40% Resistance rates across key EM’s • Standard antibiotics increasingly fail ; creating urgent unmet clinical need $3-4 Bn Addressable market size Aim for Registration & Launch: Latin America, Eurasia, GCC and South / South East Asia markets Enter 7-8 Key Markets with high CR burden in next 18-24 months Sources: Lancet

Market potential

Patient Pool Industry-leading Launch : Patient Access Building patient centric business and operating model delivering sizeable, sustainable and profitable revenue Millions of patients in Emerging Markets are waiting for the right antibiotic. Every day without access is a life at risk from carbapenem-resistant infections. 33 Investor Conference | 04 June 2026 34 Investor Conference | 04 June 2026 Abbreviations ®: Registered ~: Approximate AMR: Anti Microbial Resistance Bn: Billion BLI: Beta Lactamase Inhibitor CDSCO: Central Drugs Standard Control Organization CRO: Carbapenem Resistant Organism cUTI : Complicated urinary tract Infections Cr.: Crore EBITDA : Earnings before interest, taxes, depreciation, and amortization PBP: Penicillin-binding proteins R&D: Research and Development HABP: Hospital Acquired Bacterial Pneumonia RWE: Real world evidence ICMR: Indian Council of Medical Research INR: Indian rupee KOL: Key opinion leader LCM: Life cycle management MRSA: Methicillin-resistant